期刊
FEBS JOURNAL
卷 277, 期 23, 页码 4814-4827出版社
WILEY-BLACKWELL
DOI: 10.1111/j.1742-4658.2010.07904.x
关键词
administration routes; barriers in siRNA delivery; chemically modified RNA; in vivo disease models; nanoparticles; nonviral carriers; nucleic acid therapeutics; RNA interference; targeted delivery in vivo; viral vectors
资金
- NSF [DMR-0956091]
- Council on Research Computing and Libraries Research (UC Irvine)
- Direct For Mathematical & Physical Scien [0956091] Funding Source: National Science Foundation
- Division Of Materials Research [0956091] Funding Source: National Science Foundation
RNA interference (RNAi) has been regarded as a revolutionary tool for manipulating target biological processes as well as an emerging and promising therapeutic strategy. In contrast to the tangible and obvious effectiveness of RNAi in vitro, silencing target gene expression in vivo using small interfering RNA (siRNA) has been a very challenging task due to multiscale barriers, including rapid excretion, low stability in blood serum, nonspecific accumulation in tissues, poor cellular uptake and inefficient intracellular release. This minireview introduces major challenges in achieving efficient siRNA delivery in vivo and discusses recent advances in overcoming them using chemically modified siRNA, viral siRNA vectors and nonviral siRNA carriers. Enhanced specificity and efficiency of RNAi in vivo via selective accumulations in desired tissues, specific binding to target cells and facilitated intracellular trafficking are also commonly attempted utilizing targeting moieties, cell-penetrating peptides, fusogenic peptides and stimuli-responsive polymers. Overall, the crucial roles of the interdisciplinary approaches to optimizing RNAi in vivo, by efficiently and specifically delivering siRNA to target tissues and cells, are highlighted.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据